Results 41 to 50 of about 1,534 (92)

Effect of deferiprone in transwell-cultured confluent ECC-1 cells: Epithelial monolayer integrity.

, 2016
Cultures at maximal luminal barrier function (TER ≥ 1000 ohms / cm2) were left untreated, or were treated with deferiprone at the indicated concentrations, every day via the apical chamber and every other day via the basolateral chamber.
Myung Hee Park (176990), Bernadette M. Cracchiolo (462186), Paul E. Palumbo (462178), Michael Spino (462182), John Connelly (462188), Bart Holland (462191), Tsafi Pe’ery (462192), Axel-Rainer Hanauske (462179), Jonathan Karn (220557), Hartmut M. Hanauske-Abel (462176), Deepti Saxena (462177), Michael B. Mathews (35045), Fernando Tricta (462187), Darlene D’Alliessi Gandolfi (2793712)   +13 more
core   +1 more source

A pilot trial of deferiprone for neurodegeneration with brain iron accumulation [PDF]

, 2011
Deferiprone was shown to reverse iron deposition in Friedreich's ataxia. This multi-center, unblinded, single-arm pilot study evaluated safety and efficacy of deferiprone for reducing cerebral iron accumulation in neurodegeneration with brain iron ...
M. Balocco, Cossu G, BONUCCELLI, UBALDO, Matta G, Bonuccelli U, G. Matta, Forni GL, Abbruzzese G, U. Ruffinengo, G. L. Forni, U. Bonuccelli, Ruffinengo U, R. Galanello, R. Marchese, M. Melis, Murgia D, G. Cossu, Galanello R, ABBRUZZESE, GIOVANNI, G. Abbruzzese, S. Barella, Marchese R, Melis M, Barella S, Balocco M, D. Murgia   +25 more
core   +1 more source

FBS0701 treatment chelates intracellular erythrocytic iron to the same extent as deferiprone but unlike deferiprone, removes iron from erythrocytes.

, 2013
Aliquots 1–5×106 erythrocytes from two separate healthy donors were stained in the dark with 0.125 µM calcein-AM for 15 minutes at 37°C. Cells were washed twice with PBS and allowed to rest for 10 minutes at 37°C in the dark.
Patricia Ferrer (322100), Abhai K. Tripathi (322101), Carla Cerami Hand (322105), Hugh Young Rienhoff Jr (322107), David J. Sullivan Jr (322111), Martha A. Clark (322102)   +5 more
core   +1 more source

Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients [PDF]

, 2010
BACKGROUND: Iron overload is a predictable and life-threatening complication in patients dependent on the regular transfusion of RBCs. The aims of this study were to investigate the efficacy and safety of deferiprone in a variety of pediatric hematologic
유철주, 원성철
core   +1 more source

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial

IMPORTANCE: Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide.
Kalinowski, P, Woodward, M, Brodtmann, A, Desmond, P, Brew, B, Devos, D, Spino, M, O'Brien, TJ, Schofield, PW, Lai, R, Ellis, KA, Lim, YY, Rowe, C, Wagen, A, Goh, AMY, Maruff, P, Kyndt, C, Tricta, F, Clarnette, R, Barton, D, Salvado, O, Williams, R, Fazlollahi, A, Bush, AI, Fradette, C, Ayton, S   +25 more
core   +1 more source

Cellular toxicity of LTCC blockers and the comparison with deferiprone.

, 2014
(A) Apoptotic effects of 10 or 100 µM AML, VER and deferiprone on HL-1 cells for 72 hr were assessed by annexin V/PI flow cytometry assay. (B) HL-1 cells were challenged with 300 µM Fe(III) or Fe(II), followed by treatments of 10 or 100 µM deferiprone 20
Shing Chan (659344), Z. Ioav Cabantchik (659343), Yiu-fai Cheung (292747), Godfrey Chi-fung Chan (474934), Mei-pian Chen (659342)   +4 more
core   +1 more source

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

, 2006
Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use.
M. A. Romeo, M. D. Cappellini, C. Borgna Pignatti, G. L. Forni, P. De Stefano, BORGNA, Caterina, G. C. Del Vecchio, R. Ghilardi, M. R. Gamberini, A. Cnaan, M.D. Cappellini, A. Piga, H. Zhao   +12 more
core   +1 more source

Chitogel with deferiprone following endoscopic sinus surgery: improved wound healing and microbiome [PDF]

PUBLISHED 04 April 2024Background: Adhesion formation, sinus ostial narrowing, and presence of pathogenic bacteria are associated with poor outcomes following endoscopic sinus surgery (ESS) for chronic rhinosinusitis.
Megow, A., Wormald, P.-J., Anna Megow, Sarah Vreugde, Peter-John Wormald, Bouras, G., Cooksley, C., Clare Cooksley, Yazeed Alsuliman, Erich Vyskocil, Vreugde, S., Murphy, W., Vyskocil, E., Alsuliman, Y., George Bouras, William Murphy   +15 more
core   +1 more source

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox

, 2019
BackgroundIron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and ...
Brenda L Gallie, Amir Sabouhanian, Brenda L. Gallie (249953), Nancy F. Olivieri (6407168), Nancy F Olivieri, Amir Sabouhanian (6407171)   +5 more
core   +1 more source

Datasheet1_Chitogel with deferiprone following endoscopic sinus surgery: improved wound healing and microbiome.pdf

BackgroundAdhesion formation, sinus ostial narrowing, and presence of pathogenic bacteria are associated with poor outcomes following endoscopic sinus surgery (ESS) for chronic rhinosinusitis.
Erich Vyskocil (4739916), Anna Megow (18300424), Yazeed Alsuliman (18300427), Clare Cooksley (4169461), George Bouras (835677), William Murphy (308098), Sarah Vreugde (541061), Peter-John Wormald (541063)   +7 more
core   +1 more source